Sugammadex and Neostigmine in Pediatric Patients

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

October 25, 2023

Study Completion Date

April 15, 2024

Conditions
Postoperative VomitingPostoperative NauseaPostoperative Delirium
Interventions
DRUG

Group N; neostigmine+atropine

"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."

DRUG

GROUP S; decurarized with sugammadex.

"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."

Trial Locations (1)

34854

Marmara University, Istanbul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Marmara University

OTHER

NCT05618236 - Sugammadex and Neostigmine in Pediatric Patients | Biotech Hunter | Biotech Hunter